MKP5 allostery in MAPK regulation and signaling in the heart
MKP5 变构在心脏 MAPK 调节和信号传导中的作用
基本信息
- 批准号:10375784
- 负责人:
- 金额:$ 62.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-18 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AdoptedAllosteric SiteBindingBinding SitesBiologyCRISPR/Cas technologyCardiac developmentCatalysisCatalytic DomainCellsCellular biologyChemicalsClinicalComplexCoupledCrystallizationDataDevelopmentDiseaseEffectivenessFingerprintGenerationsGeneticGoalsHeartHeart failureInterventionKineticsKnock-inKnock-in MouseMAPK phosphataseMAPK8 geneMediatingMitogen-Activated Protein KinasesModelingMolecularMorbidity - disease rateMusOutcomePathway interactionsPharmaceutical PreparationsPharmacologyPhosphoric Monoester HydrolasesPhysiologicalPlayProtein Kinase InteractionProteomicsRegulationResolutionRoleSignal TransductionSiteSpecificityStructureTherapeuticTissuesTransforming Growth FactorsUnited StatesWorkbiophysical techniquescoronary fibrosisdruggable targetexperimental studyfibrogenesisgenetic approachin vivoinhibitorinsightmortalitymouse geneticsmutantnoveloperationp38 Mitogen Activated Protein Kinasephosphatase inhibitorphosphoproteomicspressuresmall moleculestructural biologytherapeutic targettranscriptomics
项目摘要
ABSTRACT
The catalytic activity and specificity of the mitogen-activated protein kinase (MAPK) phosphatases (MKPs) is
governed through their ability to interact with the MAPKs. The MKPs set the fidelity and kinetics of MAPK
signaling by regulating, in a spatially distinct manner, both the magnitude and duration of MAPK activity.
However, these regulatory mechanisms alone are insufficient to explain the complexity of MKP/MAPK-
mediated signaling. This is exemplified by the observation that inactivation of MKPs deliver unique, and in
some cases, non-obvious physiological and pathophysiological outcomes that has led to the realization that
MKPs represent valuable therapeutic targets for the treatment of certain diseases. We have found that MKP5,
which directly dephosphorylates p38 MAPK and JNK, is involved in the development of cardiac fibrosis, a
serious sequalae that precedes heart failure. Mice lacking MKP5 are protected from the development of
cardiac fibrosis and heart failure in a model of pressure overload. A high throughput small molecule screen
identified a first-in-class inhibitor of MKP5. Resolution of the co-crystal structure of the inhibitor in complex with
MKP5 revealed that the inhibitor bound to an allosteric site on MKP5. We hypothesize that the MKP5 allosteric
site represents an additional mode of MKP5 regulation that governs signaling specificity and that this allosteric
site represents the “Achilles heel” of MKP5 for small molecule targeting. The broad goal of this work is two-fold.
First, we will define the molecular basis for how the allosteric site regulates MKP5 catalysis and MAPK
signaling. Second, whether disruption of the allosteric site produces outcomes in a disease context that provide
proof-of-concept that if successfully “drugged” this site represents a platform for development of first-in-class
MKP inhibitors. We will execute the specifics of these two broad goals through three specific aims. Aim 1, will
employ structural biology and biophysical approaches to elucidate the structural determinants and binding
mechanisms conferred by the MKP5 allosteric site to determine how this site regulates MKP5 catalysis and
MAPK binding. A co-complex between MKP5 and p38 MAPK will be obtained to define how p38 MAPK
modulates MKP5 through the allosteric site. In Aim 2, the effects of mutants in the MKP5 allosteric site on
MAPK signaling will be determined by generating knockin cells harboring MKP5 allosteric site mutants using
CRISPR-Cas approaches. The specificity of the MKP5 allosteric site to “fine-tune” MAPK-mediated signaling
will be determined using non-biased phosphoproteomic and transcriptomic approaches. In Aim 3, the effects of
targeting the MKP5 allosteric site in cardiac fibrosis and heart failure will be determined through the generation
of a novel MKP5 allosteric site mutant knock-in mouse. These studies will define a new mode of operation for
MKP5 that will provide information on the actions of the allosteric site at the atomic level. How the MKP5
allosteric site impacts physiological signaling and the validity of the allosteric site as a “druggable” target in
disease therapeutics will be defined.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anton M Bennett其他文献
Anton M Bennett的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anton M Bennett', 18)}}的其他基金
MKP5 allostery in MAPK regulation and signaling in the heart
MKP5 变构在心脏 MAPK 调节和信号传导中的作用
- 批准号:
10552036 - 财政年份:2022
- 资助金额:
$ 62.03万 - 项目类别:
Dual-specificity phosphatase action in muscle disease
肌肉疾病中的双特异性磷酸酶作用
- 批准号:
10621754 - 财政年份:2022
- 资助金额:
$ 62.03万 - 项目类别:
Dual-specificity phosphatase action in muscle disease
肌肉疾病中的双特异性磷酸酶作用
- 批准号:
10342959 - 财政年份:2022
- 资助金额:
$ 62.03万 - 项目类别:
Yale Post-Baccalaureate Research Education Program
耶鲁大学学士后研究教育计划
- 批准号:
10686863 - 财政年份:2021
- 资助金额:
$ 62.03万 - 项目类别:
Yale Post-Baccalaureate Research Education Program
耶鲁大学学士后研究教育计划
- 批准号:
10474267 - 财政年份:2021
- 资助金额:
$ 62.03万 - 项目类别:
Yale Post-Baccalaureate Research Education Program
耶鲁大学学士后研究教育计划
- 批准号:
10113213 - 财政年份:2021
- 资助金额:
$ 62.03万 - 项目类别:
Signaling by Shp2 mutants in RASopathies
RASopathies 中 Shp2 突变体的信号传导
- 批准号:
9889163 - 财政年份:2018
- 资助金额:
$ 62.03万 - 项目类别:
Signaling by gain-of-function SHP-2 mutants in Noonan syndrome
努南综合征中功能获得性 SHP-2 突变体的信号传导
- 批准号:
8622206 - 财政年份:2012
- 资助金额:
$ 62.03万 - 项目类别:
相似海外基金
Allosteric site prediction and transmission of functional residues with atomistic graph analysis
通过原子图分析进行功能残基的变构位点预测和传递
- 批准号:
2859072 - 财政年份:2020
- 资助金额:
$ 62.03万 - 项目类别:
Studentship
Creation of novei anticancer lead compounds targeting the allosteric site of c-Met kinase
创建针对 c-Met 激酶变构位点的新型抗癌先导化合物
- 批准号:
16K08327 - 财政年份:2016
- 资助金额:
$ 62.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Studying how a general allosteric site regulates protein kinase function
研究一般变构位点如何调节蛋白激酶功能
- 批准号:
8595027 - 财政年份:2013
- 资助金额:
$ 62.03万 - 项目类别:
Studying how a general allosteric site regulates protein kinase function
研究一般变构位点如何调节蛋白激酶功能
- 批准号:
8704718 - 财政年份:2013
- 资助金额:
$ 62.03万 - 项目类别:
Studying how a general allosteric site regulates protein kinase function
研究一般变构位点如何调节蛋白激酶功能
- 批准号:
8874171 - 财政年份:2013
- 资助金额:
$ 62.03万 - 项目类别:
STRUC DETERMINATION OF METAL-SUBSTITUTED & ALLOSTERIC SITE VARIANTS OF H INFLU
金属取代物的结构测定
- 批准号:
7955561 - 财政年份:2009
- 资助金额:
$ 62.03万 - 项目类别:
EXAMINATION OF ALLOSTERIC SITE OF SEROTONIN TRANSPORTER USING TRANSGENIC MICE
使用转基因小鼠检查血清素转运蛋白的变构位点
- 批准号:
7715783 - 财政年份:2008
- 资助金额:
$ 62.03万 - 项目类别:
STRUC DETERMINATION OF METAL-SUBSTITUTED & ALLOSTERIC SITE VARIANTS OF H INFLU
金属取代物的结构测定
- 批准号:
7721325 - 财政年份:2008
- 资助金额:
$ 62.03万 - 项目类别:
ALLOSTERIC SITE STRUCTURES OF CARDIOVASCULAR CHANNELS
心血管通道的变构位点结构
- 批准号:
7215384 - 财政年份:2007
- 资助金额:
$ 62.03万 - 项目类别:
EXAMINATION OF ALLOSTERIC SITE OF SEROTONIN TRANSPORTER USING TRANSGENIC MICE
使用转基因小鼠检查血清素转运蛋白的变构位点
- 批准号:
7562646 - 财政年份:2007
- 资助金额:
$ 62.03万 - 项目类别: